Review
Oncology
Peng Du, Xuefan Wu, Kun Lv, Ji Xiong, Daoying Geng
Summary: Pituitary carcinoma is a rare and difficult-to-diagnose disease, with conventional treatments showing limited effectiveness. This article reports a case of sparsely granulated somatotroph carcinoma with a favorable treatment response to temozolomide combined with radiation therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Clinical Neurology
Mei Luo, Yiheng Tan, Wenli Chen, Bin Hu, Zongming Wang, Diming Zhu, Haosen Jiao, Chengbin Duan, Yonghong Zhu, Haijun Wang
Summary: Temozolomide demonstrates significant radiological and biochemical response rates in patients with APT and PC, leading to prolonged PFS and OS. Low/intermediate MGMT expression and functional subtype may serve as important predictors of TMZ efficacy. Combination therapy of radiotherapy with TMZ shows improved outcomes in clinical settings.
FRONTIERS IN NEUROLOGY
(2021)
Review
Clinical Neurology
Sam Ng, Mahmoud Messerer, Julien Engelhardt, Michael Bruneau, Jan Frederick Cornelius, Luigi Maria Cavallo, Giulia Cossu, Sebastien Froelich, Torstein R. Meling, Dimitrios Paraskevopoulos, Henry W. S. Schroeder, Marcos Tatagiba, Idoya Zazpe, Moncef Berhouma, Roy T. Daniel, Edward R. Laws, Engelbert Knosp, Michael Buchfelder, Henri Dufour, Stephane Gaillard, Timothee Jacquesson, Emmanuel Jouanneau
Summary: Aggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary tumors and their management is rapidly evolving. The new term Pituitary neuroendocrine tumors (PitNet) reflects a shift towards a neuro-oncological-like approach. Treatment recommendations include surgery, temozolomide, local radiotherapy, and novel therapies such as VEGF-targeted therapies and immunotherapies.
ACTA NEUROCHIRURGICA
(2021)
Article
Endocrinology & Metabolism
Pablo Remon-Ruiz, Eva Venegas-Moreno, Elena Dios-Fuentes, Juan Manuel Canelo Moreno, Ignacio Fernandez Pena, Miriam Alonso Garcia, Miguel Angel Japon-Rodriguez, Florinda Roldan, Elena Fajardo, Ariel Kaen, Eugenio Cardenas Ruiz-Valdepenas, David Cano, Alfonso Soto-Moreno
Summary: Imaging and pathology evaluation may not accurately predict the aggressiveness of pituitary tumors, but histological examination can provide useful information. Our case report highlights the importance of suspicion for malignancy in pituitary tumors with aggressive features and the need for multidisciplinary team follow-up to manage potential metastases.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Cristina Lamas, Rosa Camara, Carmen Fajardo, Pablo Remon-Ruiz, Betina Biagetti, Fernando Guerrero-Perez, Marta Araujo-Castro, Mireia Mora, Felicia Hanzu, Pedro Iglesias, Rogelio Garcia-Centeno, Alfonso Soto
Summary: In this retrospective study, temozolomide was found to be an effective medical treatment for aggressive pituitary neuroendocrine tumors and pituitary carcinomas, but may sometimes lead to tumor progression. Co-administration with radiotherapy may increase progression-free survival.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
Stephanie Du Four, Jorn Van Der Veken, Johnny Duerinck, Elle Vermeulen, Corina E. E. Andreescu, Michael Bruneau, Bart Neyns, Van Velthoven, Brigitte Velkeniers
Summary: In this article, we report a case series of five patients with pituitary carcinoma (PC) and highlight the challenges in diagnosis and treatment. PCs are rare intracranial neoplasms that usually develop from aggressive pituitary adenomas. The mean time interval from initial diagnosis to PC diagnosis was 10.7 years. Various treatment approaches, including surgery, radiotherapy, temozolomide, and immunotherapy, were used, with some patients achieving stable disease. The lack of predictive factors for an aggressive clinical course makes management challenging for PCs.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Ann McCormack
Summary: The use of temozolomide in the treatment of aggressive pituitary tumours and pituitary carcinomas has significantly improved patient survival. There is increasing interest in exploring its early use in the treatment algorithm. The overall response rate is around 40% with stable disease in 25%, demonstrating its clinical effectiveness. Combination radiotherapy and temozolomide may be more effective in patients who have not reached maximal radiation thresholds.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Biochemistry & Molecular Biology
Jonas Feldheim, Almuth F. Kessler, Julia J. Feldheim, Ellina Schulz, David Wend, Lazaros Lazaridis, Christoph Kleinschnitz, Martin Glas, Ralf-Ingo Ernestus, Sebastian Brandner, Camelia M. Monoranu, Mario Loehr, Carsten Hagemann
Summary: Glioblastoma is a fatal tumor and chemotherapy with temozolomide (TMZ) is a crucial treatment. However, TMZ treatment may lead to changes in MGMT promoter methylation and affect the migration and proliferation behavior of tumor cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Cyntanna C. Hawkins, Amber B. Jones, Emily R. Gordon, Yuvika Harsh, Julia K. Ziebro, Christopher D. Willey, Corinne Griguer, David K. Crossman, Sara J. Cooper, Sasanka Ramanadham, Ninh Doan, Anita B. Hjelmeland
Summary: Sphingolipid metabolism is dysregulated in GBM, leading to cell evasion of apoptosis. This study found that the mRNA levels of acid ceramidase, a key enzyme in S1P production, were elevated in recurrent GBM. Inhibiting acid ceramidase decreased cell growth and increased apoptosis in TMZ-resistant GBM cells, suggesting the potential utility of targeting sphingolipid metabolism in recurrent GBM.
CELL DEATH DISCOVERY
(2023)
Article
Oncology
Mario Caccese, Matteo Simonelli, Veronica Villani, Simona Rizzato, Tamara Ius, Francesco Pasqualetti, Marco Russo, Roberta Ruda, Rosina Amoroso, Luisa Bellu, Roberta Bertorelle, Francesco Cavallin, Angelo Dipasquale, Mariantonia Carosi, Stefano Pizzolitto, Daniela Cesselli, Pasquale Persico, Beatrice Casini, Matteo Fassan, Vittorina Zagonel, Giuseppe Lombardi
Summary: The study investigated the association between MGMT promoter methylation status and overall survival in glioblastoma patients, finding better survival when MGMT > 15% but a more complex, non-linear relationship between MGMT methylation and survival.
Article
Medicine, General & Internal
Carlos Perez-Lopez, Cristina Alvarez-Escola, Alberto Isla Guerrero
Summary: The treatment of non-functioning pituitary adenomas depends on symptoms, contact with the optic tract, and growth on imaging tests. Medical treatment is used after surgical and radiotherapy options are exhausted.
Article
Endocrinology & Metabolism
Andrew L. Lin, Eliza B. Geer, Nupur Lala, Gabrielle Page-Wilson, Rajiv Magge, Robert J. Young, Viviane Tabar
Summary: Everolimus shows promise as an active agent in the treatment of aggressive prolactinomas, as evidenced by biochemical response and clinical benefit in patients. Further investigation is warranted to explore its efficacy.
Article
Oncology
Maria del Mar Alvarez-Torres, Elies Fuster-Garcia, Carmen Balana, Josep Puig, Juan M. Garcia-Gomez
Summary: Despite comprehensive treatment with surgery, chemotherapy, and radiotherapy, glioblastoma patients still face a poor prognosis. Extending adjuvant chemotherapy may benefit patients with moderate vascularity and methylated MGMT, but does not show benefits for highly vascular tumors, even in the presence of MGMT methylation.
Article
Endocrinology & Metabolism
Keyi Zhang, Xuefei Shou, Hong Chen, Nidan Qiao, Wenqiang He, Zhengyuan Chen, Ming Shen, Shiqi Li, Yao Zhao, Zhaoyun Zhang, Yiming Li, Hongying Ye, Yongfei Wang
Summary: The study investigated the clinical characteristics of SCAs with positive and negative ACTH immunostaining, finding that ACTH-negative SCAs were more clinically silent and more likely to demonstrate multiple microcysts on MRI. The prevalence of SCAs, especially ACTH-negative SCAs, was substantially underestimated and should be given enough attention due to the high aggressiveness of this subtype of refractory pituitary adenoma.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Xiaohai Liu, Renzhi Wang, Mingchu Li, Ge Chen
Summary: Pituitary metastasis is a rare condition, but its incidence increases with age. Breast cancer in women and lung cancer in men are the most frequent primary origins. Misdiagnosing pituitary metastasis as primary pituitary adenoma can be challenging. This case report emphasizes the importance of differential diagnosis of invasive sellar region lesions, especially in individuals over 60 with diabetes insipidus.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Fabio Rotondo, Henriett Butz, Luis V. Syro, George M. Yousef, Antonio Di Ieva, Lina M. Restrepo, Andres Quintanar-Stephano, Istvan Berczi, Kalman Kovacs
Review
Endocrinology & Metabolism
Luis V. Syro, Fabio Rotondo, Carlos A. Serna, Leon D. Ortiz, Kalman Kovacs
Article
Oncology
S. L. Asa, O. Casar-Borota, P. Chanson, E. Delgrange, P. Earls, S. Ezzat, A. Grossman, H. Ikeda, N. Inoshita, N. Karavitaki, M. Korbonits, E. R. Laws, M. B. Lopes, N. Maartens, I. E. McCutcheon, O. Mete, H. Nishioka, G. Raverot, F. Roncaroli, W. Saeger, L. V. Syro, A. Vasiljevic, C. Villa, A. Wierinckx, J. Trouillas
ENDOCRINE-RELATED CANCER
(2017)
Article
Oncology
Joseph Di Michele, Fabio Rotondo, Kalman Kovacs, Luis V. Syro, George M. Yousef, Michael D. Cusimano, Antonio Di Ieva
PATHOLOGY & ONCOLOGY RESEARCH
(2017)
Article
Pathology
Michael Solarski, Fabio Rotondo, Luis V. Syro, Michael D. Cusimano, Kalman Kovacs
PATHOLOGY RESEARCH AND PRACTICE
(2017)
Review
Oncology
Michael Solarski, Fabio Rotondo, William D. Foulkes, John R. Priest, Luis V. Syro, Henriett Butz, Michael D. Cusimano, Kalman Kovacs
ENDOCRINE-RELATED CANCER
(2018)
Review
Oncology
Luis V. Syro, Fabio Rotondo, Leon D. Ortiz, Kalman Kovacs
ENDOCRINE-RELATED CANCER
(2018)
Article
Endocrinology & Metabolism
Ann McCormack, Olaf M. Dekkers, Stephan Petersenn, Vera Popovic, Jacqueline Trouillas, Gerald Raverot, Pia Burman
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2018)
Review
Endocrinology & Metabolism
Luis V. Syro, Fabio Rotondo, Mauricio Camargo, Leon D. Ortiz, Carlos A. Serna, Kalman Kovacs
FRONTIERS IN ENDOCRINOLOGY
(2018)
Article
Endocrinology & Metabolism
Lisa B. Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V. Syro, Daniel Kelly, Maria Fleseriu
Review
Endocrinology & Metabolism
Aydin Sav, Fabio Rotondo, Luis V. Syro, Carlos A. Serna, Kalman Kovacs
Article
Endocrinology & Metabolism
Maria Fleseriu, Michael Buchfelder, Justin S. Cetas, Pouneh K. Fazeli, Susana M. Mallea-Gil, Mark Gurnell, Ann McCormack, Maria M. Pineyro, Luis V. Syro, Nicholas A. Tritos, Hani J. Marcus
Review
Endocrinology & Metabolism
Shlomo Melmed, Ursula B. Kaiser, M. Beatriz Lopes, Jerome Bertherat, Luis Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A. H. Wass, Ken K. Y. Ho
Summary: Pituitary neoplasms are common and mostly benign, but can have diverse effects on health. Understanding the clinical biology of these neoplasms is important for implementing appropriate treatment strategies and improving quality of life and mortality.
Review
Endocrinology & Metabolism
Aydin Sav, Fabio Rotondo, Luis V. Syro, Meric A. Altinoz, Kalman Kovacs
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM
(2017)
Article
Endocrinology & Metabolism
Fabio Rotondo, Amro Qaddoura, Luis V. Syro, Jason Karamchandani, David G. Munoz, Mariam J. Arroyave, William P. Ospina, Michael D. Cusimano, Kalman Kovacs
ENDOCRINE PATHOLOGY
(2017)